Radiology, Vol 207, 767-774, Copyright © 1998 by Radiological Society of North America

ARTICLES

Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies

T Torizuka, KR Zasadny, B Recker and RL Wahl
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0028, USA.

PURPOSE: To compare kinetic modeling of 2-[fluorine-18]fluoro-2-deoxy-D- glucose (F-18 FDG) between untreated primary lung and untreated primary breast cancers by using positron emission tomographic (PET) findings and to correlate these findings with findings of in vitro studies. MATERIALS AND METHODS: Nineteen patients (12 men, seven women; age range, 49-82 years) with untreated primary lung cancer and 17 women with untreated primary breast cancer (age range, 26-65 years) underwent 1-hour dynamic F-18 FDG PET. A three-compartment model was applied to F- 18 FDG kinetics in tumors. The standard uptake value normalized for lean body mass (SUVlean) in tumors was measured 50-60 minutes after tracer injection. In vitro, thin-layer chromatography was performed to evaluate the intracellular phosphorylation of tritiated F-18 FDG in human lung cancer and breast cancer cell lines. RESULTS: At PET, lung cancer had a significantly (P < .003) higher rate constant for F-18 FDG phosphorylation (k3) and SUVlean than did breast cancer (0.164 +/- 0.150 [standard deviation] vs 0.043 +/- 0.018 and 8.25 +/- 3.28 vs 3.17 +/- 1.08, respectively). Breast cancer showed a significant correlation between k3 and SUVlean (r = .607, P < .01), although no such correlation was observed in lung cancer. In vitro studies showed phosphorylation of F-18 FDG in breast cancer cells was less complete in hyperglycemia than it was in lung cancer cells. CONCLUSION: A much lower k3 appears to be a rate-limiting factor for F-18 FDG accumulation in breast cancer, while the higher k3 in lung cancer is probably not rate limiting for F-18 FDG accumulation.

This article has been cited by other articles:

				R. I. Sharma and T. A.D. Smith Colorectal Tumor Cells Treated with 5-FU, Oxaliplatin, Irinotecan, and Cetuximab Exhibit Changes in 18F-FDG Incorporation Corresponding to Hexokinase Activity and Glucose Transport J. Nucl. Med., August 1, 2008; 49(8): 1386 - 1394. [Abstract] [Full Text] [PDF]

				T. A.D. Smith, R. I. Sharma, A. M. Thompson, and F. E.M. Paulin Tumor 18F-FDG Incorporation Is Enhanced by Attenuation of P53 Function in Breast Cancer Cells In Vitro J. Nucl. Med., September 1, 2006; 47(9): 1525 - 1530. [Abstract] [Full Text] [PDF]

				R. Kumar, V. A. Loving, A. Chauhan, H. Zhuang, S. Mitchell, and A. Alavi Potential of Dual-Time-Point Imaging to Improve Breast Cancer Diagnosis with 18F-FDG PET J. Nucl. Med., November 1, 2005; 46(11): 1819 - 1824. [Abstract] [Full Text] [PDF]

				D. Pellegrino, A. A. Bonab, S. C. Dragotakes, J. T. Pitman, G. Mariani, and E. A. Carter Inflammation and Infection: Imaging Properties of 18F-FDG-Labeled White Blood Cells Versus 18F-FDG J. Nucl. Med., September 1, 2005; 46(9): 1522 - 1530. [Abstract] [Full Text] [PDF]

				J. Tseng, L. K. Dunnwald, E. K. Schubert, J. M. Link, S. Minoshima, M. Muzi, and D. A. Mankoff 18F-FDG Kinetics in Locally Advanced Breast Cancer: Correlation with Tumor Blood Flow and Changes in Response to Neoadjuvant Chemotherapy J. Nucl. Med., November 1, 2004; 45(11): 1829 - 1837. [Abstract] [Full Text] [PDF]

				J. J.M. van der Hoeven, N. C. Krak, O. S. Hoekstra, E. F.I. Comans, R. P.A. Boom, D. van Geldere, S. Meijer, E. van der Wall, J. Buter, H. M. Pinedo, et al. 18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer J. Clin. Oncol., April 1, 2004; 22(7): 1253 - 1259. [Abstract] [Full Text] [PDF]

				A. K. Buck and S. N. Reske Cellular Origin and Molecular Mechanisms of 18F-FDG Uptake: Is There a Contribution of the Endothelium? J. Nucl. Med., March 1, 2004; 45(3): 461 - 463. [Full Text]

				T. Higashi, T. Saga, Y. Nakamoto, T. Ishimori, M. H. Mamede, M. Wada, R. Doi, R. Hosotani, M. Imamura, and J. Konishi Relationship Between Retention Index in Dual-Phase 18F-FDG PET, and Hexokinase-II and Glucose Transporter-1 Expression in Pancreatic Cancer J. Nucl. Med., February 1, 2002; 43(2): 173 - 180. [Abstract] [Full Text] [PDF]

				L. I. Wiebe FDG Metabolism: Quaecumque Sunt Vera ... J. Nucl. Med., November 1, 2001; 42(11): 1679 - 1681. [Full Text] [PDF]

				T. Mochizuki, E. Tsukamoto, Y. Kuge, K. Kanegae, S. Zhao, K. Hikosaka, M. Hosokawa, M. Kohanawa, and N. Tamaki FDG Uptake and Glucose Transporter Subtype Expressions in Experimental Tumor and Inflammation Models J. Nucl. Med., October 1, 2001; 42(10): 1551 - 1555. [Abstract] [Full Text] [PDF]

				H. Zhuang, M. Pourdehnad, E. S. Lambright, A. J. Yamamoto, M. Lanuti, P. Li, P. D. Mozley, M. D. Rossman, S. M. Albelda, and A. Alavi Dual Time Point 18F-FDG PET Imaging for Differentiating Malignant from Inflammatory Processes J. Nucl. Med., September 1, 2001; 42(9): 1412 - 1417. [Abstract] [Full Text] [PDF]

				N. Avril, C. A. Rose, M. Schelling, J. Dose, W. Kuhn, S. Bense, W. Weber, S. Ziegler, H. Graeff, and M. Schwaiger Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations J. Clin. Oncol., October 20, 2000; 18(20): 3495 - 3502. [Abstract] [Full Text] [PDF]

				L. Aloj, C. Caraco, E. Jagoda, W. C. Eckelman, and R. D. Neumann Glut-1 and Hexokinase Expression: Relationship with 2-Fluoro-2-deoxy-D-glucose Uptake in A431 and T47D Cells in Culture Cancer Res., September 1, 1999; 59(18): 4709 - 4714. [Abstract] [Full Text] [PDF]

				P. D. Shreve, Y. Anzai, and R. L. Wahl Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants RadioGraphics, January 1, 1999; 19(1): 61 - 77. [Abstract] [Full Text] [PDF]